Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States - BioSpace
Nexcella, an Immix Biopharma subsidiary, is on track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 in mid-2024 at U.S. sites, including New York City. The NEXICART-2 trial aims to enroll 40 patients over 18 months, focusing on safety and efficacy. NXC-201 has FDA and EMA Orphan Drug Designation.
Related Clinical Trials
Reference News
Immix Biopharma announced Memorial Sloan Kettering Cancer Center as the lead site for its NXC-201 clinical trial targeting relapsed/refractory AL Amyloidosis. NXC-201, a CAR-T cell therapy, is undergoing a Phase 1b trial to assess its safety and efficacy, with potential to revolutionize treatment for AL Amyloidosis and other autoimmune diseases.
Nexcella, an Immix Biopharma subsidiary, is on track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 in mid-2024 at U.S. sites, including New York City. The NEXICART-2 trial aims to enroll 40 patients over 18 months, focusing on safety and efficacy. NXC-201 has FDA and EMA Orphan Drug Designation.